TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06344442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin
Description: low-dose arginine-vasopressin supplementation group: Vasopressin will be administered by continuous infusion. AVP will be used to a final concentration of 0.12 U/ml. The vasopressor infusion will be titrated to maintain an MAP of at least 65 mmHg. The study-drug infusion will be started at 5 ml/h and increased by 2.5 ml/h to achieve a maximum target rate of 30 ml/h, so that AVP doses ranged from 0.01 to 0.06 U/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine will be administered by continuous infusion. Norepinephrine will be used with final concentrations of 120 microg/ml. The vasopressor infusion will be titrated to maintain an MAP of at least 65 mmHg. The study-drug infusion will be started at 5 ml/h and increased by 2.5 ml/h to achieve a maximum target rate of 30 ml/h, so that NE doses ranged from10 to 60 microg/min.
Study: NCT05492604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination
Description: Cinical examination carried out during a consultation for the follow-up of the patient

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical examination
Description: Cinical examination carried out during a consultation for the follow-up of the patient
Study: NCT04899349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: Metformin XR (tablets) administered at a starting dose of 500mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 500 mg once a day to 2000 mg once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR
Description: Metformin XR (tablets) administered at a starting dose of 500mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 500 mg once a day to 2000 mg once a day.
Study: NCT06374381

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: PEACE Online Resources
Description: The PEACE online resource includes self-paced training modules that cover the foundations of caregiver coaching, caregiver perspectives towards coaching, strategies for aligning with caregivers and gaining buy-in for coaching, evidence-based strategies to empower caregivers from marginalized backgrounds, and strategies to improve collaboration and cohesion among providers working with the same child. Each module includes brief example videos, easy-to read infographics, tip sheets, and checklists to guide implementation. A virtual communication application, Slack, facilitates frequent communication, enhances social networks among providers, and creates social norms related to the use of caregiver coaching. Providers can post questions or suggestions, share resources, and receive updates about other providers' accomplishments. Consultants frequently post encouraging messages and progress updates to increase motivation and shared norms for coaching.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEACE Weekly Group Facilitation
Description: Facilitation comprises interactive problem solving and support, a shared understanding of need for improvement, and a supportive interpersonal relationship. Providers participate in 12 weekly group facilitation meetings for one hour virtually with an expert consultant focused on auditing providers' fidelity to caregiver coaching through role-play and performance feedback. Each group meeting aligns with content from the PEACE online resource library modules.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEACE Weekly Individual Facilitation
Description: Individual facilitation is delivered virtually for one hour each week for eight weeks with a consultant focused on reflection and problem solving any identified implementation barriers, as well as practice and performance feedback.
Study: NCT05678920

Intervention type: OTHER
Intervention: patient-administered questionnaires
Description: patient-administered questionnaires (MEOWS): Obstetric early warning systems are recommended to provide timely recognition, treatment and early referral of critically ill or developing patients. The development of early warning systems from simple bedside observation charts arose from the knowledge that physiological disturbances precede critical illness. Thanks to these charts, the fact that the patient's findings are in the risky value ranges allows the clinician to evaluate the patient earlier and in detail. MEOWS is a simple screening tool for maternal morbidity.
Study: NCT05030857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG4716
Description: From Day 3 to Day 14, participants will receive GLPG4716 tablets once daily in fasted state. On Day 8 GLPG4716 will be administered in fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: On Days 1, 3 and 13, participants will receive a single oral dose of MDZ as an oral solution in fasted state.
Study: NCT06546878

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (Phase I) - nurse intervention
Description: The intervention consists of applying CR program (phase I ) following the Guidlines of American Association of Cardiovascular and Pulmonary Rehabilitation. The program was applied by adapting it to the patient, varying the intensity and frequency of the sessions, according to the FITT_VP acronym.~This phase consists of functional respiratory rehabilitation and motor rehabilitation exercises. Each session is divided into three parts, starting with a warm-up with breathing and isometric exercises, then the so-called peak, which consists of specific endurance/aerobic exercises, and at the end, as a recovery phase, relaxation exercises with stretching are instructed.~Also, health education sessions for patients/caregiver.
Study: NCT05492604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional scales
Description: The Clinical scales are as follows : MRC (Medical Research Scale), ONLS (Overall Neuropathy Limitations Scale), R-ODS (Rasch-built Overall Disability Scale) , INCAT (Inflammatory Neuropathy Cause and Treatment) The functional scales are used as part of the usual care of the patient in the neurology department

Intervention type: OTHER
Group type: OTHER
Intervention: Functional scales
Description: The Clinical scales are as follows : MRC (Medical Research Scale), ONLS (Overall Neuropathy Limitations Scale), R-ODS (Rasch-built Overall Disability Scale) , INCAT (Inflammatory Neuropathy Cause and Treatment) The functional scales are used as part of the usual care of the patient in the neurology department

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Walking test
Description: Walking test over 10 metres at a comfortable speed on the GAITRITE® walkway, fitted with FEETME® soles at the same time. The 10-metre test will be repeated 5 times, with a 2-minute break between each test.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Walking test
Description: Walking test over 10 metres at a comfortable speed on the GAITRITE® walkway, fitted with FEETME® soles at the same time. The 10-metre test will be repeated 5 times, with a 2-minute break between each test.
Study: NCT04899349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin + metformin XR
Description: Dapagliflozin + metformin XR administered as a single tablet combination at a starting dose of 5 mg dapagliflozin + 500 mg metformin XR orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 5 mg dapagliflozin + 500 mg metformin XR orally once daily to 10 mg dapagliflozin + 2000 mg metformin XR once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin (tablet) at a starting dose of 5mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 5 mg to 10 mg once daily
Study: NCT06235151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper Cu 64 PSMA I&T
Description: Radiopharmaceutical PET imaging tracer injected intravenously for staging of prostate cancer.
Study: NCT06446804

Intervention type: OTHER
Intervention: None, pure observationnal study
Description: Pure observatonnal study
Study: NCT05664880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: 2 MCG Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsule to 2 MCG Paricalcitol Oral Capsule
Study: NCT05832190

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Patients receiving during 3 months before the surgery usual general dietary recommendations regarding balanced diet comprising legumes and fruits, meat or equivalent, dairy products and starch and bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Patients receiving during 3 months before the surgery usual general dietary recommendations regarding balanced diet comprising legumes and fruits, meat or equivalent, dairy products and starch and bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Patients receiving during 3 months before the surgery usual general dietary recommendations regarding balanced diet comprising legumes and fruits, meat or equivalent, dairy products and starch and bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Patients receiving during 3 months before the surgery usual general dietary recommendations regarding balanced diet comprising legumes and fruits, meat or equivalent, dairy products and starch and bread

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Biotin supplement
Description: 1 capsule per day of Biotin 450µg during 3 months before the surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Biotin supplement
Description: 1 capsule per day of Biotin 450µg during 3 months before the surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber supplement
Description: 3 servings per day of PureLean® Fiber, a powdered blend of fibers and prebiotics, during 3 months before the surgery

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber supplement
Description: 3 servings per day of PureLean® Fiber, a powdered blend of fibers and prebiotics, during 3 months before the surgery
Study: NCT06567041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: NNC0519-0130 will be administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.
Study: NCT06282523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HMP app
Description: The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HMP app
Description: The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HMRP web app
Description: The HMRP web app is a meditation-based web-based app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMRP provides core content, with instruction administered through a curriculum of guided practices. HMRP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HMRP web app
Description: The HMRP web app is a meditation-based web-based app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMRP provides core content, with instruction administered through a curriculum of guided practices. HMRP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.
Study: NCT05434949

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Three blood samples to be taken at 08.00, 10.00 and 12.00 on day 1 of the study.~The following day, after an overnight fast, a blood sample will be taken at 8.00, followed by a standardized breakfast provided by the study team at 8.30, and then two further blood samples at 10.00 and 12.00.

Intervention type: OTHER
Intervention: Analyses of samples
Description: C4 will be measured in surplus serum from 30 adult lipid patients before starting on lipid-lowering therapy (either statin of PCSK9 therapy) and then again 3 months after starting on therapy. Blood samples will be collected as part of routine lipid management, no additional samples are required.
Study: NCT06189508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXT007
Description: In all groups, the NXT007 single dose administration will occur in the morning of Day 1 under fasted conditions. Study treatment will occur via the route of administration and at the site of injection specified for each group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXT007
Description: In all groups, the NXT007 single dose administration will occur in the morning of Day 1 under fasted conditions. Study treatment will occur via the route of administration and at the site of injection specified for each group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXT007
Description: In all groups, the NXT007 single dose administration will occur in the morning of Day 1 under fasted conditions. Study treatment will occur via the route of administration and at the site of injection specified for each group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXT007
Description: In all groups, the NXT007 single dose administration will occur in the morning of Day 1 under fasted conditions. Study treatment will occur via the route of administration and at the site of injection specified for each group.
Study: NCT05636995

Intervention type: DIAGNOSTIC_TEST
Intervention: Aldosterone/Renin Ratio
Description: Blood sample collected to measure the aldosterone/renin ratio for the primary hyperaldosteronism screening.

Intervention type: DIAGNOSTIC_TEST
Intervention: Aldosterone/Renin Ratio
Description: Blood sample collected to measure the aldosterone/renin ratio for the primary hyperaldosteronism screening.
Study: NCT05088213

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suction mini percutaneous nephrolithotomy
Description: 18Fr suction sheath (Weili, China) was inserted, and 12Fr mini-nephroscope was used, kidney stones was fragmented by pneumatic lithotriptor (LithoClast Master, Switzerland) or Ho:YAG laser（0.8-1.0W\*20-30Hz）, and stone fragments was sucked out with the suction sheath.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard percutaneous nephrolithotomy
Description: 24-30Fr sheath was inserted, and 20Fr nephroscope (Richard Wolf, Germany) was used, kidney stones was disintegrated and sucked out by ultrasonic-lithotripter (LithoClast Master, EMS, Switzerland or ShockPluse-SE, Olympus).
Study: NCT04440592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117
Description: MT-7117

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05204355

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Patients will be imaged using MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Patients will be imaged using MRI

Intervention type: DRUG
Intervention: Hyperpolarized Xe129
Description: Hyperpolarized Xe129 will be used to image the lungs of a subset of participants.
Study: NCT06169657

Intervention type: DEVICE
Intervention: Body-weight-supported treadmill training (BWSTT)
Description: Walking on a treadmill in a harness with body weight support as needed

Intervention type: DEVICE
Intervention: Body-weight-supported treadmill training (BWSTT)
Description: Walking on a treadmill in a harness with body weight support as needed

Intervention type: DEVICE
Intervention: Body-weight-supported treadmill training (BWSTT)
Description: Walking on a treadmill in a harness with body weight support as needed

Intervention type: DEVICE
Intervention: Body-weight-supported treadmill training (BWSTT)
Description: Walking on a treadmill in a harness with body weight support as needed

Intervention type: DEVICE
Intervention: EksoNR exoskeleton gait training
Description: Walking in the EksoNR exoskeleton

Intervention type: DEVICE
Intervention: EksoNR exoskeleton gait training
Description: Walking in the EksoNR exoskeleton

Intervention type: DEVICE
Intervention: EksoNR exoskeleton gait training
Description: Walking in the EksoNR exoskeleton

Intervention type: DEVICE
Intervention: EksoNR exoskeleton gait training
Description: Walking in the EksoNR exoskeleton

Intervention type: DEVICE
Intervention: Overground gait training
Description: Walking overground in a harness with body weight support as needed

Intervention type: DEVICE
Intervention: Overground gait training
Description: Walking overground in a harness with body weight support as needed

Intervention type: DEVICE
Intervention: Overground gait training
Description: Walking overground in a harness with body weight support as needed

Intervention type: DEVICE
Intervention: Overground gait training
Description: Walking overground in a harness with body weight support as needed
Study: NCT05204355

Intervention type: DIAGNOSTIC_TEST
Intervention: HRCT
Description: High Resolution Computer Tomography
Study: NCT06197893

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gingival unit graft+modified sling suture technique
Description: The GUG was obtained from the maxillary premolar area. A sulcular incision including the marginal gingival tissue, and two vertical incisions, including the distal and mesial papillae, was made in the palatial parts of the premolars. Then, the incision lines were combined and a 1-1.5 mm thick graft of the desired dimensions was dissected. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using a modified sling suture technique. First, the needle was passed through the graft slightly apical to the mesial papilla on the buccal side and removed from the lingual aspect including lingual papilla. Subsequently, on the distal side, the needle was passed from the lingual side to the buccal side, and it was passed through the graft slightly apical to the distal papilla and removed from the lingual gingiva again. Then it was knotted on the buccal graft by returning to the buccal starting point on the mesial side.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gingival unit graft and conventional suture technique
Description: The GUG was obtained from the maxillary premolar area. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using conventional suture technique. Conventional suture technique includes a horizontal matrix suture and 2 simple sutures. First the coronal part of the dissected graft was fixed to the recipient bed with a horizontal matrix suture, then with 2 simple sutures along the vertical incision line from mesial and distal sides with 5/0 polypropylene suture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional graft and modified sling suture technique
Description: Conventional graft dimensions were determined with aluminum foil and the foil was placed in the palatinal region at the level of the maxillary premolars, at least 2 mm away from the free gingival margin of the adjacent teeth. The exterier edges of the foil were drawn with a scalpel and the 1-1.5 mm thick graft was dissected from the donor site. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using a modified sling suture technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional graft and conventional suture technique
Description: Conventional graft obtained from the palatinal region at the level of the maxillary premolars, at least 2 mm away from the free gingival margin of the adjacent teeth. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using conventional suture technique.
Study: NCT05038592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tagraxofusp-erzs
Description: Given IV
Study: NCT05473676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Training Period
Description: Participants will engage in robot assisted gait training on at least 5 days/week for at least 30 minutes each day, for a total period of 12 weeks.
Study: NCT06645834

Intervention type: DEVICE
Group type: OTHER
Intervention: Smart MDI System
Description: The Smart MDI system consists of the InPen™ system and Simplera™ system.~The InPen™ system includes a reusable smart bolus insulin pen injector with Bluetooth combined with the InPen™ app to help users take insulin doses.~And InPen™ app which communicates with the InPen™ injector and compatible continuous glucose monitoring (CGM) devices to collect and display information on insulin delivered by the injector as well as current and past glucose values.~The Simplera™ system consists of a disposable integrated sensor-transmitter platform (Simplera™ Sensor) and the Simplera™ app which receives data from the Simplera™ sensor via Bluetooth Low Energy (BLE) radio signal
Study: NCT05306418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8
Description: For treatment part 1, all participants will start on once-weekly treatment and continue on this regimen until week 26. For treatment part 2, starting at week 26, all participants will be offered the choice to remain on once-weekly or switch to once-monthly dosing.~Mim8 will be injected with a thin needle into the skin